<DOC>
	<DOCNO>NCT02013791</DOCNO>
	<brief_summary>This study evaluate new ophthalmic formulation cyclosporine ( Restasis® X ) patient moderate severe dry eye disease two stage . Up 3 dos study Stage 2 base result Stage 1 . No patient participate Stage 1 participate Stage 2 study .</brief_summary>
	<brief_title>Phase 2 Study New Ophthalmic Formulation Cyclosporine ( Restasis® X ) Patients With Dry Eye Disease</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Moderate severe dry eye disease eye Bestcorrected visual acuity ( BCVA ) 20/100 good eye Use cyclosporine preparation within 3 month Use topical medication , artificial tear , eye within 1 month Use contact lenses either eye within 1 month Stage 2 : Participation Stage 1 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>